以含硒羟基磷灰石 (Se-HA) 为代表的硒掺杂钙磷生物材料，为同步实现骨肉瘤切除后的骨缺损修复和肿瘤复发抑制提供了新策略。然而现有的Se-HA设计、制备和功能评价往往关注抗肿瘤方面，忽略了促骨修复功能。本项目首次提出一种抗肿瘤肽修饰的仿生矿化Se-HA纳米材料，以胶原作为模板在LSS体系中矿化，一方面形成类天然骨的微观结构，提高生物相容性；另一方面提供大量活性基团，有利于抗肿瘤肽的表面修饰。课题针对肿瘤抑制和骨缺损修复，分别选择了具有骨肉瘤凋亡诱导作用的MSP-4及免疫调节和促骨修复功能的LL37两种抗肿瘤肽。它们的引入不仅能改变材料表面电荷特征，促进材料-细胞相互作用；还能凭借各自的生物学功能，增强材料的抗肿瘤和促骨修复活性。课题通过体外细胞实验及体内骨肉瘤复发抑制、骨缺损修复综合研究考察和评价新材料的双功能性，将为发展新一代骨肉瘤临床治疗材料和策略提供重要理论基础。

The selenium-doped hydroxyapatite (Se-HA), one typical representative of selenium-doped calcium-phosphate biomaterial, shows great promise of simultaneously defect repair of osteosarcoma resection and tumor recurrence inhibition. However, the current research of Se-HA paid too much attention on anti-tumor somehow ignored bone repair. Herein we design and fabricate an anticancer peptide modified biomimetic mineralized Se-HA (ACP-BM-Se-HA). Collagen is used as a template to induce mineralization through an LSS reaction, which leads to natural bone-like microstructure formation, significant biocompatibility improvement, as well as sufficient active groups for further conjugation of anticancer peptide (ACP). In this project, two representative ACPs, MSP-4 with osteosarcoma apoptosis-inducing capacity and LL37 with immunoregulatory and bone repair functions are selected due to their unique biological potential. The introduction of these two ACPs will not only promote material-cell interaction by changing the surface charge of the Se-HA, but also enhance anti-tumor and bone repair properties. We will carry out in vitro cell experiments and in vivo assays including in situ osteosarcoma recurrence inhibition and bone defect repair, to systemically evaluate the resulting performance of ACP-BM-Se-HA. This project is aimed to provide fundamental theoretical support for developing novel materials and strategies for clinical osteosarcoma therapy.